BTG International has launched a next-generation treatment option, DC Bead LUMI, for cancer patients in Canada, marking its first worldwide market commercialisation.

Based on the technology platform of the company’s DC Bead, the DC Bead LUMI is a radiopaque embolic drug-eluting bead that can be loaded with the chemotherapy drug doxorubicin to treat hepatocellular carcinoma (HCC), a commonly occurring primary liver cancer.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It can also be loaded with another chemotherapy drug, irinotecan, to treat malignant colorectal cancer metastasised to the liver (mCRC).

Drug-eluting beads are used in trans-arterial chemoembolisation (TACE), a minimally invasive liver cancer treatment that deliberately blocks blood supply to the tumour and locally delivers a controlled, sustained dose of chemotherapy directly to the tumour.

"The LUMI TACE beads really delivered. They were what one hoped for, so it was easy to see under fluoroscopy, single shot and cone beam CT."

The DC Bead LUMI aids in optimising patient treatment by enabling real-time visible confirmation of bead location during and after the embolisation procedure.

This allows interventional radiologists to have more control simultaneously discovering under-treatment regions, thereby allowing precise evaluation of the completeness of tumour treatment and enhanced end-point determination, with long-lasting radiopacity to support follow-up management.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The treatment option was first performed by Sunnybrook Health Sciences Centre in Canada.

Sunnybrook Health Sciences Centre vascular / interventional radiologist staff Dr Chris Dey said: “The LUMI TACE beads really delivered. They were what one hoped for, so it was easy to see under fluoroscopy, single shot and cone beam CT.

“You can appreciate actual bead deposition in the liver for the first time, flow patterns much more reliably and make intra-procedural adjustments or determine end points more precisely.”